Clinical trials: Diabetes, Type 1
Diabetes, Diabetes Mellitus, Type 1
First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.
The study is comparing the new medicine NNC9204-1513 with a standard therapy of glucagon (GlucaGen®). This is the first time NNC9204-1513 is given to humans.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT03444467
- Testing
- NNC9204-1513, Glucagon
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study for Patients With Diabetes Mellitus (IOPA)
The purpose of this study is to compare glycemic control (HbA1c) in Chinese patients with type 1 or type 2 diabetes when treated with insulin lispro low mixture and human insulin 30/70.
- Trial name
- IOPA (NCT00420095)
- Testing
- Human insulin 30/70, Insulin lispro low mix
- Where
- 4 sites in China
- Volunteers
- 117 people
- Sponsor
- Eli Lilly and Company
Insulin Dependent Diabetes, Non Insulin Dependent Diabetes
Evaluation and Comparison of Noninvasive Blood Glucose Concentrations
Comparison of noninvasive glucose measurement performance versus standard invasive reference measurements.
- Conditions
- Insulin Dependent Diabetes, Non Insulin Dependent Diabetes, Gestational Diabetes
- Trial name
- NCT01745900
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- VeraLight, Inc.
Type I Diabetes
Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes
Objectives Primary study objective: To determine whether orally-administered ladarixin versus placebo adjunctive therapy improves insulin sensitivity in overweight, insulin-resistant (IR) type 1 Diabetic (T1D) adult subjects.
- Trial name
- NCT05035368
- Testing
- Ladarixin
- Where
- United States
- Sponsor
- Dompé Farmaceutici S.p.A
Diabetes Mellitus
Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects
This is a phase 1, randomized, double-blind, placebo-controlled, 2-way crossover study to evaluate the effect of AMG 151 on 24-hour ambulatory blood pressure and glucose levels in subjects with type 2 diabetes mellitus who are on…
- Trial name
- NCT01755442
- Testing
- AMG 151
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Amgen
Diabetes, Diabetes Mellitus, Type 1
Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes
This trial is conducted in Europe. The aim of this trial is to compare different ratios of explorative formulations, not similar to the proposed commercial formulation, of IDegAsp (co-formulation of insulin degludec/insulin…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01865305
- Testing
- insulin degludec/insulin aspart 30, insulin degludec/insulin aspart 40, insulin degludec/insulin aspart 50
- Where
- Germany
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending-doses of TAK-875 in subjects with type 2 diabetes mellitus.
- Trial name
- NCT00949091
- Testing
- TAK-875
- Volunteers
- 60 people
- Sponsor
- Takeda
Diabetes, Diabetes Mellitus, Type 1
Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes
This trial is conducted in Europe. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir once daily injection compared to insulin detemir twice daily…
- Trial name
- ADAPT (NCT00117780)
- Testing
- insulin detemir, insulin aspart
- Where
- 3 sites in Belgium, France and 1 more
- Volunteers
- 520 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
A Survey to Evaluate Diabetes Management, Control, Complications and Psychosocial Aspects of Diabetic Patients in Philippines
This study is conducted in Asia. The aim of this observational study is to describe the diabetes management, control status and complication profile in a diabetic population of Philippines.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- DiabCare Asia (NCT00874159)
- Testing
- No treatment given
- Where
- Philippines
- Volunteers
- 770 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Obesity
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.
- Conditions
- Type 1 Diabetes, Obesity, Overweight
- Trial name
- SURPASS-T1D-2 (NCT06962280)
- Testing
- Tirzepatide
- Where
- 79 sites in United States, Argentina and 8 more
- Volunteers
- 465 people
- Sponsor
- Eli Lilly and Company
Diabetes, Autoimmune
Safety, Tolerability, Immunological and Clinical Efficacy of Multiple Subcutaneous Doses of DiaPep277 in Latent Autoimmune Diabetes in Adults (LADA)
Randomized, double-blind, parallel-group study to evaluate safety and efficacy of multiple subcutaneous doses of DiaPep277 in patients with Latent Autoimmune Diabetes in Adults (LADA).
- Trial name
- NCT00058981
- Testing
- DiaPep277
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- DeveloGen Israel, Ltd.
Type 1 Diabetes Mellitus
Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects
The study was a Phase 2, multicounty, multicenter, non-confirmatory, investigator- and subject masked, randomized, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CFZ533 on…
- Trial name
- CCFZ533X2207 (NCT04129528)
- Testing
- CFZ533
- Where
- 12 sites in Belgium, Germany and 4 more
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus (T2DM)
Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus
This study is a first-in-human randomized, double-blind (Investigator and subject), placebo controlled single ascending dose study that will enroll approximately 40 (6 active/2 placebo per dose group) adult male and female…
- Trial name
- NCT01835730
- Testing
- PE0139 Injection
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes
This trial is conducted in Africa, Europe, North and South America and Oceania. The aim of this trial is to compare the effect and safety on blood glucose control in pregnant women with type 1 diabetes of a modern insulin…
- Trial name
- NCT00474045
- Testing
- insulin detemir, NPH insulin, insulin aspart
- Where
- 98 sites in Argentina, Australia and 15 more
- Volunteers
- 470 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Type 1 Diabetes
Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)
The purpose of this postmarket clinical investigation is to evaluate the levels of glycemic control, quality of life, and satisfaction, as well as the patient experience, and acute diabetes complication rates provided by the…
- Conditions
- Diabetes, Type 1 Diabetes, Diabetes Mellitus
- Trial name
- NCT07317102
- Testing
- Omnipod 5
- Where
- 24 sites in France
- Volunteers
- 152 people
- Sponsor
- Insulet Corporation
Gastroparesis
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
This study is a randomized, double-blind, placebo controlled trial designed to confirm the symptomatic effects of camicinal treatment vs. placebo, on gastroparesis symptoms in type 1 and 2 diabetic subjects with gastroparesis.
- Trial name
- NCT02210000
- Testing
- Camicinal
- Where
- 34 sites in United States
- Volunteers
- 114 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1
Feasibility Trial Testing the Bionic Pancreas With ZP4207
The purpose of this study was to determine whether the Bionic Pancreas with ZP4207 (dasiglucagon*) was feasible to improve glycemic control in adults with type 1 diabetes mellitus.
- Trial name
- dasiglucagon (NCT02971228)
- Testing
- Insulin Lispro, ZP4207 (dasiglucagon), Glucagon
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Zealand Pharma
Type 1 Diabetes, Type 2 Diabetes
Feasibility Study of New Subcutaneous Glucose Sensor With Recording Devices
The purpose of Phase 3 Group is to evaluate the impact of acetaminophen on the performance of Guardian Sensor (3) during 11 days of wear (approximately 264 hours) in subjects with insulin requiring diabetes,18-75 years of age.
- Trial name
- NCT04020822
- Testing
- Guardian Sensor (3)
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes, Type 1 Diabetes Mellitus With Hypoglycemia
Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes
First in Human, pilot investigation An Open Label, Monocentric, Pilot Study Evaluating Safety of ExOlin® in Patients with Poorly Controlled Type 1 Diabetes with High Glucose Fluctuations, Prone to Severe Hypoglycemia
- Trial name
- Pilot'Ex (NCT05221359)
- Testing
- ExOlin®, Insulin aspart
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Defymed
Type 1 Diabetes Mellitus
Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule
This is a randomized, placebo-controlled, parallel group, multicenter, double-blind Phase 2a, 2-arm study. The goal of this Phase 2a study is to assess safety and efficacy of brivekimig in comparison to placebo to preserve β-cell…
- Trial name
- T1D OBTAIN (NCT06812988)
- Testing
- Brivekimig
- Where
- 24 sites in United States, Argentina and 6 more
- Volunteers
- 84 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.